Putting public health needs at the centre of antibiotic drug development to address the crisis of antimicrobial resistance (AMR). https://gardp.org/this-is-big/https://bsky.app/profile/gardp.bsky.socialhttps://bsky.app/profile/gardp.bsky.social/post/3mtl23i5njc2b🎙️ Join our AMR Discussions webinar on 3 Sept (14:30-15:30 CEST) As expert researchers leave or retire, how can we attract and retain the talent needed to secure the future of antibiotic development? 🔗Register: https://attendee.gotowebinar.com/register/2981739652574190429?source=Bluesky21 Aug 2026 05:35 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mtl23i5njc2bhttps://bsky.app/profile/gardp.bsky.social/post/3mtgejvuc6s2o🌍 Since 2018, REVIVE has helped bring together researchers from clinical, industry and academic settings to share expert #AMR knowledge. 📚 Through a growing library of free resources, REVIVE supports early-stage antimicrobial researchers. 🌐Explore everything #REVIVE has to offer: revive.gardp.org19 Aug 2026 08:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mtgejvuc6s2ohttps://bsky.app/profile/gardp.bsky.social/post/3mtdx5dd6dk2e📝 New in STAT: What if the global antibiotic crisis isn’t just about overuse, but underuse too? New research in @thelancet.com points to overuse in some parts of the world and underuse in others. Peter Beyer explores what this means for access and stewardship. 🔗 https://www.statnews.com/2026/08/18/antibiotic-underuse-overuse-resistance-aware/18 Aug 2026 09:54 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mtdx5dd6dk2ehttps://bsky.app/profile/gardp.bsky.social/post/3mtazzznl222y📖Have you read GARDP's Annual Report 2025 yet? Read how GARDP is turning vision into reality, and why the journey is far from over. 🔗Read the report: https://gardp.org/annual-report-2025/ #AnnualReport #AMR #AntimicrobialResistance #GlobalHealth #GARDP17 Aug 2026 06:08 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mtazzznl222yhttps://bsky.app/profile/gardp.bsky.social/post/3mszjicoxdc2q#FungalAwarenessWeek2026 is almost here! Join REVIVE on 17 September for a webinar exploring recent advances to overcome pharmacokinetic & pharmacodynamic challenges in antifungal therapy. Hear from leading experts & take part in a live Q&A. 📅 Register: https://register.gotowebinar.com/register/754048829754636117?source=Bluesky14 Aug 2026 06:23 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mszjicoxdc2qhttps://bsky.app/profile/gardp.bsky.social/post/3msuhw2dpys2x🏆 NUZOLVENCE® (zoliflodacin) has been nominated for the 2026 Prix Galien USA Award for Best Pharmaceutical Product This first new antibiotic developed solely for gonorrhoea in decades is developed in a public-private partnership between GARDP and Innoviva Specialty Therapeutics tinyurl.com/jja4paej12 Aug 2026 06:12 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3msuhw2dpys2xhttps://bsky.app/profile/gardp.bsky.social/post/3msrwy2h4bs2yA new Letter to the Editor in the Journal of Translational Medicine welcomes the draft ICH E21 guideline and calls for action to close evidence gaps for pregnant and breastfeeding women. Congrats to Tammy Meyers, the Collaborative Group and @dndi.org. 📖Read: https://link.springer.com/article/10.1186/s12967-026-08509-z11 Aug 2026 06:03 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3msrwy2h4bs2yhttps://bsky.app/profile/gardp.bsky.social/post/3mspmsbhbos2o🦠 Last year, our campaign #ThisIsBig highlighted the scale of antimicrobial resistance. This year, we're focusing on what it takes to change its trajectory. 💥 AMR is BIG. Our response is BIGGER. Follow us as we spotlight our partnerships and how innovations can drive a bigger response to AMR.10 Aug 2026 07:56 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mspmsbhbos2ohttps://bsky.app/profile/gardp.bsky.social/post/3mshvflzyp223New antibiotics may reach patients faster, but approval is only the beginning. The latest REVIVE Antimicrobial Viewpoint by Ursula Theuretzbacher explores why coordinated, adaptive post-approval evidence generation is essential. 🔗 tinyurl.com/yyhuvjff Developed in collab with @cmicomms.bsky.social07 Aug 2026 06:08 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mshvflzyp223https://bsky.app/profile/gardp.bsky.social/post/3msfsh22uqc2u📝💊 A new SECURE report highlights a critical challenge in the fight against #AMR: access to essential antibiotics remains uneven across the WHO African Region. 📖 Read the report: https://www.who.int/publications/i/item/WHO-AFRO-2026-13439-53213-83244 @who.int06 Aug 2026 10:10 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3msfsh22uqc2uhttps://bsky.app/profile/gardp.bsky.social/post/3mscu3juquc2wA new RIVM risk assessment identifies #AMR as the leading international public health risk for the Netherlands over the coming decade & recognizes that tackling AMR requires stronger preparedness, international collaboration & continued investment in antibiotic R&D. 📖 https://www.rivm.nl/publicaties/global-risk-assessment-of-public-health-in-netherlands-better-prepared-for-future#abstract_en05 Aug 2026 06:02 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mscu3juquc2whttps://bsky.app/profile/gardp.bsky.social/post/3ms5t22pphs27GARDP has signed a memorandum of understanding with ILDONG Pharmaceutical to explore how to strengthen future supply and access pathways for flomoxef, an antibiotic being studied for neonatal sepsis.03 Aug 2026 06:00 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3ms5t22pphs27https://bsky.app/profile/gardp.bsky.social/post/3mrysvjttns2kWe're hiring! GARDP is looking for a Consultant – Medical Affairs & Clinical Coordination in Delhi to support access to a priority antibacterial treatment through clinical evidence, regulatory engagement and expert collaboration. 📍 Delhi | 📅 6-month consultancy (extendable) 📩 aroy@gardp.org01 Aug 2026 06:14 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mrysvjttns2khttps://bsky.app/profile/gardp.bsky.social/post/3mrwavwbmq22eFor decades, the global pipeline for developing and delivering new antibiotics has worked in reverse. In his latest @telegraph.co.uk op-ed, Peter Beyer explains how Thailand's fast-track approval of zoliflodacin could help turn that model on its head. 🔗 https://www.telegraph.co.uk/global-health/science-and-disease/new-drug-for-super-gonorrhoea-points-to-better-antibiotics/31 Jul 2026 05:47 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mrwavwbmq22ehttps://bsky.app/profile/gardp.bsky.social/post/3mrrhiiykuc2sIn Luska, Zambia, alongside #RAAC2026, GARDP brought together government representatives, researchers, clinicians, advocates and AMR experts to help inform its 2027–2031 strategy. The most effective solutions are grounded in regional expertise and shaped by those closest to the challenge.29 Jul 2026 08:01 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mrrhiiykuc2shttps://bsky.app/profile/gardp.bsky.social/post/3mrmfh4snak2a🚨 This is BIG! The Thai FDA has approved NUZOLVENCE® (zoliflodacin), a first-in-class oral antibiotic for the treatment of uncomplicated urogenital gonorrhoea, just 6 months after its initial approval by the US FDA. 🔗 https://gardp.org/thai-fda-approves-nuzolvence-zoliflodacin-just-six-months-after-us-authorization/27 Jul 2026 07:41 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mrmfh4snak2ahttps://bsky.app/profile/gardp.bsky.social/post/3mrerfmly2s2n✨ We've got a fresh new look! The new GARDP website is live — our biggest digital evolution since we were founded. Explore our programmes, projects, research, stories and more through a faster, more intuitive experience. 🌐 gardp.org Bacteria are evolving. So must we. #AMR #GlobalHealth24 Jul 2026 06:54 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mrerfmly2s2nhttps://bsky.app/profile/gardp.bsky.social/post/3mra4nmkqdk2q⚠️ People across Latin America and the Caribbean face delays in accessing Reserve antibiotics, even after these medicines have been approved elsewhere. Our new review explores why, and highlights opportunities to improve access through coordinated regional action. 🔗 Read: tinyurl.com/4xjm5ay922 Jul 2026 10:32 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mra4nmkqdk2qhttps://bsky.app/profile/gardp.bsky.social/post/3mr2mwok3ss26A major milestone for GARDP's #NeoSep1 trial 🎉 The first baby has now been enrolled in Vietnam, continuing the expansion of this landmark neonatal sepsis trial from Africa into Asia.20 Jul 2026 06:07 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mr2mwok3ss26https://bsky.app/profile/gardp.bsky.social/post/3mqt36746mk2nREVIVE was created by GARDP to preserve critical AMR expertise and connect the global antimicrobial R&D community. Explore the platform and discover resources designed to support antimicrobial innovation. 🔗 https://gardp.pulse.ly/z48xmfdeso17 Jul 2026 06:01 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mqt36746mk2nhttps://bsky.app/profile/gardp.bsky.social/post/3mqljrarwys2b📢Late-breaker abstract submissions are now open for #GAMRIC2026! 📩 Submit your abstract: https://www.gamric.org/programme/abstracts/ 🎟️ Register by 15 July (tomorrow) to secure the early registration rate: https://www.gamric.org/registration-travel-grants/ @escmid.bsky.social14 Jul 2026 06:01 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mqljrarwys2bhttps://bsky.app/profile/gardp.bsky.social/post/3mqj3jl7gmc2m🤝 GARDP has signed an MoU with Venus Remedies Limited under the India AMR Co-Development Programme (I-AMR-CDP). As a Knowledge Partner, we'll contribute scientific expertise to help evaluate promising antibacterial candidates emerging from India's research ecosystem.13 Jul 2026 06:40 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mqj3jl7gmc2mhttps://bsky.app/profile/gardp.bsky.social/post/3mqbhtdv2st2e🚨 Late-breaker abstract submissions are now open for #GAMRIC2026! Submit by 22 July. ⏰ Don't forget: the early registration deadline is 15 July. 📝 Abstracts: https://gamric.pulse.ly/ojkyzslkik 🎟️ Register: https://gamric.pulse.ly/1cw3wtn5e6 @escmid.bsky.social10 Jul 2026 05:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mqbhtdv2st2ehttps://bsky.app/profile/gardp.bsky.social/post/3mq74lcucqs22The antibiotics we need most are often the hardest to develop. A new BBC StoryWorks feature explores why antibiotic innovation needs a new model, and highlights GARDP's public health-driven approach to R&D, access and stewardship. Read more: https://www.bbc.com/storyworks/innovation-unlocked/gsk-amr09 Jul 2026 07:33 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mq74lcucqs22https://bsky.app/profile/gardp.bsky.social/post/3mpxfxpz75t2eEvery year, millions of newborns develop sepsis. For many, the antibiotics available are no longer effective. We're proud to announce the launch of the #NeoSep1 clinical trial at Aga Khan University Hospital in Pakistan, helping advance better treatment options for newborns with sepsis. #AMR06 Jul 2026 05:59 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mpxfxpz75t2ehttps://bsky.app/profile/gardp.bsky.social/post/3mpskf2qg6s2n📢 GARDP has joined 7 other Product Development Partnerships in calling for sustained investment in EDCTP under FP10 and other EU funding frameworks. 🔗 tinyurl.com/2t3tjbkk @globalhealthedctp3.bsky.social @ec.europa.eu @europevaccine.bsky.social @dndi.org @mmv.org @tballiance.bsky.social04 Jul 2026 07:35 +0000at://did:plc:6ohydvsnh2j4lbvm4lp6ec4e/app.bsky.feed.post/3mpskf2qg6s2n